Clinovo launches the latest version of its Electronic Data Capture (EDC) system ClinCapture.
Sunnyvale, CA. December 19th, 2014. Clinovo launches the latest version of its Electronic Data Capture (EDC) system ClinCapture. With the new release, sponsor companies, contract research organizations (CROs) and researchers will be able to streamline the development and management of clinical trials by creating and managing electronic case report forms (CRFs) without relying on professional services. With these new features, ClinCapture becomes the only free, full-validated EDC in the world.
“We are very proud of this new release, which will deliver unprecedented speed of implementation, flexibility and functionality to users,” said Glenn Keet, CEO of Clinovo. “The new features of ClinCapture will give users the ability to create CRFs without having any sort of advanced programming or IT management skills, which represents a great leap forward in terms of usability for the industry.”
Through this release, ClinCapture is bringing its open source EDC system to the next level by offering at no cost a fully validated hosting environment. Furthermore, the new ClinCapture Builder is a do-it-yourself portal that enables users to fully create, deploy and manage studies on their own, from one central location. Because ClinCapture is cloud-based, users can manage one or several clinical trials from anywhere, at any time. Designing and creating CRFs will be faster and more straightforward with the drag-and-drop amenities, not to mention complex edit checks creation made simple-clinical trial managers can have these necessities completed in just a few days, making the processes extremely cost effective.
“The self-service portal sets ClinCapture apart from other EDCs,” said Marc Desgrousilliers, CTO at Clinovo. “Efficiency is essential in this industry, and having everything you need to build CRFs at your fingertips is exceptional. ClinCapture is also the only open source EDC with an integrated, intuitive randomization function and is one of the only WHO drug certified EDCs -proving Clinovo’s technological leadership.”
Clinovo’s intuitive technologies are designed to cater specifically to meet customers’ needs, budgets and infrastructures and are steering the industry; they offer best-in-class tools at a fraction of the cost. Clinovo seeks to provide the best way to streamline clinical trials to allow life science companies to save time and focus on what is most important to their business.
About Clinovo:
Clinovo is a technology focused Contract Research Organization (CRO) headquartered in the Silicon Valley. Clinovo streamlines clinical trials for life science companies globally by developing validated, intuitive eClinical systems. Clients claim over 50% cost savings using Clinovo’s Electronic Data Capture (EDC) system ClinCapture®, and CDISC Express, the first open source CDISC conversion tool. Services also include Biometrics Services, Staffing Solutions, and TechTrainings.
Contact information
Sophie McCallum
Director of Operations, Clinovo408-773-6258
sophie.mccallum@clinovo.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.